Trials / Recruiting
RecruitingNCT06572930
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
Assessment of the Role of Serum FSH Monitoring During Ovarian Stimulation and Identification of an Optimal Range for Expected Normal Responders
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- ART Fertility Clinics LLC · Academic / Other
- Sex
- Female
- Age
- 18 Years – 39 Years
- Healthy volunteers
- Accepted
Summary
This study examines if monitoring serum Follicle Stimulation Hormone (FSH) levels can predict oocyte yield and progesterone levels, considering factors like age, baseline FSH, Antral Mullerian Hormone (AMH), antral follicle count, body weight, kidney function, and urinary FSH. The aim is to find a minimum FSH level that ensures optimal ovarian response and enables tailored FSH dosages for better outcomes.
Detailed description
Ovarian stimulation typically uses transvaginal ultrasound to monitor follicle growth and endometrial condition, with some clinics also tracking serum estradiol and progesterone levels, but often neglecting serum Follicle Stimulation Hormone (FSH). FSH is essential for follicle development, yet its levels can vary widely among women receiving the same dose due to factors like body weight, renal function, and ovarian reserve. This study aims to identify a minimum effective FSH threshold that ensures optimal follicular growth while avoiding excess administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gonal-f (gonadotropin) | Women will be given 300 IU Gonal-F daily from cycle day 2 or 3. Gonal F will be injected at 8 pm daily. They will all receive cetrorelix acetate 250 mcg/day (Cetrotide) subcutaneously from stimulation day 5 onwards until and including the trigger day. Cetrotide will be administered at 08:00 am. |
Timeline
- Start date
- 2024-12-16
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-08-27
- Last updated
- 2025-02-24
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT06572930. Inclusion in this directory is not an endorsement.